Table 1 Patient characteristics.

From: Retinal Microvasculature and Visual Acuity after Intravitreal Aflibercept in Diabetic Macular Edema: An Optical Coherence Tomography Angiography Study

Eyes/patients, no.

23/23

Age (years) (mean ± SD; range)

64.3 ± 11.9 (43–84)

Sex, no. (%)

 Men

17 (74)

 Women

6 (26)

Eye, no. (%)

 Right

11 (48)

 Left

12 (52)

Diabetes, no. (%)

 NPDR

14 (61)

 PDR

9 (39)

BCVA before treatment

 Landolt C acuity chart (mean; range)

0.52 (0.15–1.0)

 LogMAR (mean ± SD)

0.28 ± 0.23

CRT before treatment (µm) (mean ± SD; range)

484 ± 133 (313–828)

Duration of follow-up (months) (mean ± SD; range)*

8.5 ± 5.6 (3–25)

Number of injections during follow-up, no. (mean ± SD; range)

2.6 ± 1.3 (1–8)

  1. SD, standard deviation; BCVA, best-corrected visual acuity; logMAR, logarithm of the minimum angle of resolution; CRT, central retinal thickness.
  2. *Follow-up duration between the initial optical coherence tomography angiography (OCTA) examination before treatment and the OCTA examination after treatment for diabetic macular edema.
Back to article page